ZENUM Technologies: The Fastest SARS-COV-2 Rapid Testing Kit
Emidio Sacramento, Founder and CEO
“In the midst of every crisis, lies a great opportunity” – Albert Einstein
When the COVID-19 pandemic broke out last year, the healthcare sector found itself at the epicentre of an unprecedented storm. The pandemic forced every healthcare professional (HCPs) to be on a war footing for months to help contain the outbreak. This crisis also highlighted many areas in the current care delivery model where the HCPs had to improve their efficiency in fighting the ongoing pandemic better. Take the paradigm of medical prediagnosis, for example. If the COVID-19 pandemic made one thing clear, it was the importance of having a proper testing regime as the foremost step to reduce the chances of the viral outbreak significantly. However, the current market available disease testing kits were less than ideal for such aggressive testing because they would take hours, if not days, to show the diagnostic results. This situation, therefore, started creating a massive gap in the care delivery model, leading the HCPs to invest in advanced testing kits.
Enter ZENUM Technologies.
ZENUM was quick to change the status quo of conventional medical prediagnosis with its COVID-19 antigen-antibody rapid test kits, marketed under the brand name ZEKMED. “With our rapid test kits, HCPs can now facilitate accurate medical screening for the COVID-19 virus within a mere 15-minute timeline,” says Emidio Sacramento, founder and CEO of ZENUM Technologies.
How It All Began…
Before launching its ZEKMED range of products, ZENUM was involved in developing secure biometric applications for the identity and access management (IAM) industry.But the company soon realised that analysing the biometrics data with AI can also unlock the path for more informed and accurate prediagnosis of certain diseases like skin cancer, glaucoma, Parkinson’s, Alzheimer, and more. To explore this idea, ZENUM joined hands with medical project collaborators and like-minded partners and entered the healthcare space to develop tools for prediagnosis of glaucoma. The success of this project marked the starting point of ZENUM’s journey in the healthcare space, especially putting a seal of approval on ZENUM’s approach in the realm of medical prediagnosis. Drawing on the experience the company had gathered through its ventures over the years, ZENUM has now recalibrated its competencies to tackle the challenges of the COVID-19 pandemic head-on.
ZENUM’s IgG/IgM antibody rapid test kits (both ZEKMED and ZEKNANO) are proving to be critical tools in effective containment of the SARS-COV-2 virus
It is also important to note that ZENUM has recently introduced ZEKNANO—a nanofluidic rapid test kit—for strengthening the ZEKMED suite of products further. ZEKNANO helps HCPs detect IgG/IgM antibodies specific to the COVID-19 virus within five minutes.
ZEKNANO can also aid HCPs in determining disease severity score and efficacy of vaccination, along with identification of up to 14 different types of respiratory allergies. To make this as accurate as possible, ZEKNANO uses ZENUM Artificial Neural Nets (ANNs). These AI-driven neural networks use a series of algorithms to function like a human brain, only at a much higher speed. The ZENUM ANNs represent the behaviour of the whole COVID-19 problem in one neural net and increase the overall disease detection accuracy of ZEKNANO to almost 100 percent. And because of such astounding capabilities, ZENUM’s IgG/IgM antibody rapid test kits (both ZEKMED and ZEKNANO) are proving to be critical tools in the effective containment of the SARS-COV-2 virus.
At this juncture, elaborating on how these rapid testing kits fare better than other testing kits, Sacramento talks about an instance where a surgeon was tested positive right before an important surgery. As the concerned surgeon was the only one who had the specific expertise to perform the surgery, he had to be retested to be doubly sure. Fortunately, the same healthcare facility was using ZENUM’s rapid testing kits in one of its departments. When the surgeon got retested using ZENUM’s new testing kits, the result showed a negative outcome, ruling out the previous result. This last-minute help from ZENUM’s rapid testing kit enabled the surgeon to carry out the operation without any worry. “Even though we have many instances of success, this is one of our fondest memories. Because we didn’t just save one life, but two,” underscores Sacramento.
Moving ahead with such success stories, ZENUM is now laser-focused on empowering every healthcare professional with ZEKMED and ZEKNANO in the coming months. “Mass testing, along with fast and accurate patient triage, is the only reliable defence against COVID-19 before any vaccine reaches enough people,” avers Sacramento. And as made clear by the founder-CEO, ZENUM will continue playing a critical role in mounting the strongest defence against COVID-19 and any future viral outbreak. “We are perfectly positioned to revolutionise the medical prediagnosis space even in the post-COVID-19 era,” concludes Sacramento
Description ZENUM has recently introduced ZEKNANO—a nanofluidic rapid test kit—for strengthening the ZEKMED suite of products further. ZEKNANO helps HCPs detect IgG/IgM antibodies specific to the COVID-19 virus within five minutes. ZEKNANO can also aid HCPs in determining disease severity score and efficacy of vaccination and identify up to 14 different types of respiratory allergies. For this, ZEKNANO uses ZENUM Artificial Neural Nets (ANNs). These AI-driven neural networks use a series of algorithms to function like a human brain, only at a much higher speed. The ZENUM ANNs represent the behaviour of the whole COVID-19 problem in one neural net and increase the overall disease detection accuracy of ZEKNANO to almost 100 percent.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: